Pharmacoeconomic review report: AbobotulinumtoxinA (Dysport therapeutic) (Ipsen Biopharmaceuticals Canada, Inc.)
AbobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) is a botulinum neurotoxin subtype indicated to reduce the subjective symptoms and objective signs of cervical dystonia (CD, spasmodic torticollis) in adults, and is available in single-use vials of 300 U and 500 U at submitted prices of $428.40 and...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, August 2017
|
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | AbobotulinumtoxinA (aboBoNTA, Dysport Therapeutic) is a botulinum neurotoxin subtype indicated to reduce the subjective symptoms and objective signs of cervical dystonia (CD, spasmodic torticollis) in adults, and is available in single-use vials of 300 U and 500 U at submitted prices of $428.40 and $714.00, respectively. The recommended initial dose of aboBoNTA is 500 U intramuscularly as a divided dose among affected muscles in patients with and without a prior history of treatment with botulinum toxin. Re-treatment of 250 U to 1,000 U divided among affected muscles is recommended when the effect of a previous injection has diminished, but no sooner than 12 weeks after the previous injection. The manufacturer is requesting that aboBoNTA be reimbursed in line with its indication |
---|---|
Item Description: | "Version: Final." |
Physical Description: | 1 PDF file (16 pages) illustrations |